Clinical Trials Directory

Trials / Completed

CompletedNCT04479098

Effects of Training and Detraining on Postmenopausal Breast Cancer Survivors

Effects of Training and Detraining on Body Composition and Inflammatory, Oxidative and Lipid Profiles of Postmenopausal Breast Cancer Survivors Undergoing Tamoxifen Treatment

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
14 (actual)
Sponsor
Federal University of Uberlandia · Academic / Other
Sex
Female
Age
40 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The present study aimed to verify the effects of resistance exercise training and successive detraining on body composition, lipid profile, muscle strength, oxidative stress, and inflammatory markers of postmenopausal breast cancer survivors undergoing tamoxifen treatment.

Detailed description

The present study aimed to verify the effects of 12 weeks of resistance exercise training and successive 12 weeks of detraining on body composition (Body Mass, Body Mass Index, Fat Mass, and Fat-Free Mass), lipid profile (Triglycerides, Total Cholesterol, LDL-Cholesterol, HDL-Cholesterol), muscle strength (1RM test), oxidative stress (Thiobarbituric acid reactive substances,Non-Protein Thiols, Catalase activity, and Superoxide Dismutase), and inflammatory markers (Interferon γ, Tumor Necrosis Factor α, interleukin 6 , Adiponectin, and Interleukin 4) of postmenopausal breast cancer survivors undergoing tamoxifen treatment.

Conditions

Interventions

TypeNameDescription
OTHERResistance exercise trainingThe exercise training program will last 12 weeks, with a frequency of three sessions per week, held on Mondays, Wednesdays, and Fridays. Each session will last approximately 50 minutes. Whenever the maximum number of pre-established repetitions is successfully performed, the intensity will be increased by 5 to 10%. All sessions will be supervised by trained professionals.
OTHERExercise detrainingThe exercise detraining will last 12 weeks without exercise.

Timeline

Start date
2016-07-01
Primary completion
2017-07-31
Completion
2018-06-30
First posted
2020-07-21
Last updated
2020-07-21

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT04479098. Inclusion in this directory is not an endorsement.